PO.CL05.02 · 临床研究

Assessing donor heterogeneity in CAR-T cells with massively parallel mixed lymphocyte reactions

海报缩略图:Assessing donor heterogeneity in CAR-T cells with massively parallel mixed lymphocyte reactions
编号 5205 展板 23 时间 4/21 09:00–12:00 区域 Section 40 主讲 Lujing Wu, MS
分会场 Adoptive Cell Therapy 2
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Lujing Wu1, Lina Mohamad1, Michelle Mantilla1, Johnathan Lu1, Ansuman T. Satpathy2, Theodore Roth3

1Pathology, Stanford University, Stanford, CA,2Stanford University,3Stanford University, San Francisco, CA

摘要 Abstract

Donor heterogeneity is a major source of variation in CAR-T cell functions which leads to inconsistencies in both clinical efficacy and pre-clinical studies to enhance CAR-T cell functions. However, assessing T cell donor heterogeneity with a large sample size is costly and time-consuming. Here, we developed a Massively Parallel - Mixed Lymphocytes Reaction (MP-MLR) assay that allows pooling and simultaneously testing of CAR-T cells from multiple human donors. Combining with pooled genetic perturbation technologies, we conducted pooled screening in more than 50 T cell donors for enhanced CAR-T cell proliferation under repetitive tumor stimulations, with a library of candidate genetic perturbations proposed to enhance CAR-T or T cell functions. While we identified genetic perturbations with consistent effect on CAR-T cells across donors, the majority of perturbations showed various levels of donor dependencies, and this observation was confirmed with arrayed validation of selected perturbations on specific donors. Furthermore, we performed multi-parameters pooled screening in-vitro and in-vivo for systematic discovery of generalizable and donor specific genetic perturbations enhancing CAR-T cell pre-clinical therapeutic efficacies. Overall, we presented an efficient and cost-effective strategy for assessing donor variabilities in CAR-T cells, predicting patient specific effects of genetic perturbations on CAR-T cells efficacies, and potentially identifying of personalized optimal genetic perturbation for enhancing CAR-T cell functions.
利益披露 Disclosure
L. Wu, None.. L. Mohamad, None.. M. Mantilla, None.. J. Lu, None.

在会议检索中打开